Objectives: To compare both economic and clinical impact of alternative cervical cancer (CC) screening strategies for women 25-65 years old using different algorithms with primary screening methods including cytology alone or hrHPV test and genotyping. MethOds: Screening and diagnosis of CC were modeled by a decision tree while the natural history of the disease was simulated by a Markov model using published available data. The compared strategies were: 1) triennially hrHPV testing with 16/18 genotyping and reflex cytology 2) triennially HPV testing with reflex genotyping and reflex cytology and 3) annually cytology alone. Clinical inputs were derived from the HERMES local trial. Unit costs for the resources used were obtained from the official price lists while the HPV test cost was based on the private's sector prices. In the absence of relevant data, the cost of treating cervical intraepithelial neoplasia (CIN2+) and invasive CC was based on the respective Spanish costs which were converted to 2014 Greek values using the relevant Consumer Price Index and Purchasing Power Parity exchange rate. Results: Strategy 1 was proved to be the dominant option as it was estimated to be less costly and more effective. In more detail, cytology alone detected 58% and 52% of CC and CIN2+ cases, respectively while strategies 1 and 2 managed to detect 94% and 85% of CC and CIN2+cases,respectively. In terms, of CCs missed, strategy 3 appears to miss 24 incidents annually in contrast to 18 of strategies 1 and 2. The annual cost of strategy 1 was estimated at € 14,568,412 compared to the cost of strategy 2 and 3 which was estimated at € 38,109,522 and € 18,209,511, respectively. cOnclusiOns:
Objectives: Our objective was to study the economic impact of the four main endovascular treatment strategies for femoropopliteal arterial disease on payers in the German healthcare system, using up-to-date clinical evidence and current reimbursement amounts. MethOds: We estimated latest clinical performance of percutaneous transluminal angioplasty (PTA), bare metal stents (BMS), drug-coated balloons (DCB), and drug-eluting stents (DES) by performing a systematic search for studies published through 2014 that reported target lesion revascularization (TLR) as an endpoint. 24-month TLR rates were estimated for each treatment weighted by sample size. We updated a previously published decision-analytic Markov model to assess budget impact to payers of the four index procedure strategies using 2015 reimbursement rates for Germany and considering up to one reintervention. Results: Twenty-nine studies were included. Pooled 24-month probabilities of TLR were 16.5%, 19.4%, 26.9%, and 39.6% for DCB, DES, BMS, and PTA, respectively. Over 24 months, DES had the lowest budget impact to payers of € 3,799, closely followed by DCB (€ 3,913) . The corresponding amounts for BMS and PTA were € 4,189 and € 4,451, respectively. Comparing the most effective (DCB) to the least effective therapy (PTA), we found a number needed to treat (NNT) of 4.34. This suggests that for every four patients treated with DCB as opposed to PTA, one TLR could be avoided over 24 months, at overall cost savings to the healthcare system. cOnclusiOns: Latest clinical evidence suggests that drug-coated balloons provide the most favorable clinical outcome among the considered endovascular treatments for femoropopliteal artery disease. Our updated economic analysis finds DES and DCB to also be associated with lowest cost to payers in the German healthcare system, closely followed by drug-eluting stents. These results, based on larger evidence base, confirm earlier findings. Objectives: IBS is considered a diagnosis of exclusion based on several laboratory and diagnostics procedures to exclude other organic conditions. A novel IBS diagnostic blood panel has been developed which tests for the presence of two biomarkers associated with IBS-D. This analysis estimates the cost impact to the Italian healthcare system by introducing this test into the diagnostic pathway. MethOds: A budget impact model was based on a cost-minimization decision model developed to compare the costs associated with two possible diagnostic pathways: (1) diagnostic pathway with a novel IBS diagnostic blood panel and (2) exclusionary diagnostic pathway and applied to the Italian population 18-65yrs old. Model structure was based on current literature and guidance from IBS expert clinicians. Direct medical expenses for laboratory tests, diagnostic procedures and visit costs were included in Euros and weighted by utilization rates provided by practicing gastroenterologists in Italy. Indirect cost estimate was based on the literature and only included time off work, adjusted for per capita income in Italy. Results: Colonoscopy, ultrasound and SBFT were the most common diagnostic (instrumental) procedures reported with estimated utilization rates of 50%, 90% and 35%, respectively. Corresponding charges were € 312.50, € 70 and € 300, respectively. Estimated total base case charges for the IBS diagnostic panel pathway (assumes 75% of test positive patients receive IBS-D treatment) vs the exclusionary pathway were € 1,351 vs € 1,425, respectively. If clinicians use the test 50% of the time for the 50% of the estimated 447,275 people who might have IBS-D who seek treatment, net savings to the Italian healthcare system is € 27,581,982. Cost neutrality occurs if 49% of the "test positive" patients seek IBS standard care. Related costs were calculated according to Greek NHS official prices. The analysis was undertaken from a Greek third-party payer perspective. Results: According to the model, the reduction in expenditures related to diagnosis and prognosis/monitoring with NT-proBNP use were estimated at € 6.8 and € 3.2 million/year respectively. The projected net savings, considering the cost of NT-proBNP implementation (€ 718,000), were calculated at € 9.3 million. NT-proBNP testing also generated reduced use of health care resources, by preventing 1,890 initial hospitalizations/year, leading to 10,235 fewer hospitalization days in general ward and 3,232 in intensive care unit, and avoiding 491 hospital readmissions/year. cOnclusiOns: The overall reductions in hospitalizations and length of stay, achieved by early diagnosis and prognosis of HF with the implementation of NT-proBNP, could generate cost-savings and increase hospitals' efficiency and productivity.
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PMD28 clInIcal anD BuDgEt IMPact oF usIng a MolEcular tEst to DEtEct Kras MutatIons In MEtastatIc colorEctal cancEr PatIEnts In DEnMarK
Cheng I 1 , Hertz D 2 , Huang J 1 , Poulios N 1 1 Roche Molecular Systems, Inc., Pleasanton, CA, USA, 2 GfK, Wayland, MA, USA Objectives: Existing guidelines recommend determination of RAS mutation status in patients with metastatic colorectal cancer (mCRC) as anti-epidermal growth factor receptor (anti-EGFR) therapies are ineffective in tumors with RAS mutations. The cobas® KRAS Mutation Test (cobas test) detects twelve mutations in KRAS exon 2 and seven mutations in exon 3, whereas the therascreen KRAS RGQ PCR Kit (therascreen test) detects seven overlapping mutations in KRAS exon 2. We estimated the potential clinical and economic impact of using the cobas test versus the therascreen test in all mCRC patients in Denmark. MethOds: A budget impact model was developed from the Danish healthcare perspective. Model inputs were obtained/estimated from the literature (e.g. 1,260 annual mCRC cases were estimated). Treatment patterns were from Roche data on file. Sensitivity and specificity were assumed to be the same as positive percent agreement and negative percent agreement comparing to Sanger sequencing, which were 96.9% and 88.7% for cobas, 94.2% and 87.5% for therascreen. Drug and treatment-related costs were calculated from the national pharmaceutical procurement service (Amgros) and Danish national tariffs, respectively. The model calculated the average treatment cost for mCRC patients over 5 years, using median time on treatment and median overall survival. Costs were presented in 2015 Euros (1 Euro = 7.46021DKK). Results: Using the cobas test resulted in a reduction of 63 patient-months lost due to inappropriate care (avoiding anti-EGFR therapies in mutant patients) and an improvement in median overall survival. Using cobas KRAS testing reduced the costs of inappropriate care by € 991K and decreased monthly cost per patient by € 3, while having a minor increase (€ 105K, 0.2%) in healthcare costs. cOnclusiOns: Using the cobas test with better sensitivity and broader mutation coverage of KRAS was associated with a neutral budget impact and may improve patient outcomes by reducing the likelihood of receiving inappropriate care in mCRC patients.
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IntroDuctIon oF an organIzatIonal MoDEl oF tElEMEDIcInE In ManagEMEnt oF oral antIcoagulant thEraPy: a BuDgEt IMPact analysIs FroM ItalIan PayEr PErsPEctIvE
Dionisi M 1 , Santomauro M 2 , Santagada V 2 , Santomauro MA 2 , Garofalo G 2 , Vosa C 2 , Paolini D 1 1 Roche Diagnostics S.p.A., Monza, Italy, 2 Federico II University of Naples, Napoli, Italy Objectives: Oral Anticoagulant Therapy (OAT) with antivitamin K antagonists for prevention of thromboembolic and vascular events requires a frequent monitoring of prothrombin time and a dose adjustment to maintain the intensity of anticoagulation within a safe and effective range. The objective of the study was to quantify the budget impact after the introduction of the decentralized monitoring model for OAT patients. This model creates a link between specialized hospitals and pharmacies in the territory using Point-of-Care coagulometer CoaguChek and the telemedicine system TaoWeb, guaranteeing fewer adverse events thanks to increased accessibility to the service, compared to the centralized monitoring model and non-specialized monitoring model, and an elevated standard of quality. MethOds: A comparative analysis was carried out on three patient management models following the prospective of NHS with a time horizon of five years, taking the following into account: pharmaceutical treatments, patient monitoring and adverse events. The rate of adverse events was estimated from scientific literature and the consumption of resources was quantified taking into consideration the DRG tariffs and the outpatient national tariff list. Results: The adoption of the decentralized monitoring model compared to the centralized and non-specialized model leads to an annual saving of € 236.45 and € 525.15, respectively. Considering a target population of 491,093 patients requiring OAT and the monitoring model distribution among patients is 1.7% with the decentralized model, 86.4% with the centralized model and 11.9% with the non-specialized model. Assuming an incremental adoption rate of 6% per year of decentralized monitoring, the model predicted an annual cost saving of over € 43.3 million by its fifth year. cOnclusiOns: Despite initial higher investments for Point-of-Care coagulometer and the telemedicine technology, the decentralized monitoring model for OAT patients allows a budgetary saving compared to centralized monitoring model and non-specialized monitoring model with a potential increase of patient quality of life. 
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